Cognizant Technology Solutions said it has reached a proposed settlement in a stockholder derivative suit that had been ...

Freedom Holding Corp. said it completed an offering of 2,374,356 shares of common stock and raised nearly $300 million in ...

Ceribell, Inc. (NASDAQ: CBLL) has received FDA 510(k) clearance for its next-generation Clarityⓡ algorithm, making it the first and only AI-powered point-of-care electroencephalography (EEG) ...

WisdomTree, Inc. (NYSE: WT) has announced its definitive agreement to acquire Atlantic House Holdings Limited, a London-based systematic manager specializing in defined outcome and derivatives-driven ...

Summit Therapeutics Inc. (NASDAQ: SMMT) has announced that the U.S. Food and Drug Administration (FDA) has accepted its biologics license application (BLA) seeking approval for Ivonescimab in ...

Transocean Ltd (NYSE: RIG) and Valaris Limited (NYSE: VAL) have announced a definitive agreement to combine the two companies under an all-stock transaction valued at approximately $5.8 billion. The ...

Bitfarms has completed its U.S. redomiciliation and will now operate as Keel Infrastructure, with the company’s shares set to trade under the new ticker KEEL on Nasdaq and the Toronto Stock Exchange ...

Credo Technology recently released its 10-K report. Credo Technology Group Holding Ltd. designs and sells high-speed connectivity products for optical and electrical Ethernet and PCIe applications, ...

MoonLake Immunotherapeutics said week 52 data from its phase 3 VELA program showed 67.2% of patients treated with sonelokimab achieved HiSCR75 at one year, while 33.1% reached HiSCR100 and 26.0% ...

Orion Group Holdings, Inc. has completed the acquisition of J.E. McAmis, Inc. and JEM Marine Leasing LLC for approximately $60 million. This acquisition is expected to advance Orion’s long-term ...

Helios Technologies, Inc. (NYSE: HLIO) has announced significant changes to its finance and accounting leadership team, with Michael Connaway joining as Chief Financial Officer and Jeremy Evans being ...

AbbVie said it will buy Apogee Therapeutics for $135.11 a share in cash, valuing the biotech at about $10.9 billion. The deal gives AbbVie a pipeline of clinical-stage inflammatory and immunology ...